Astellas Pharma Ltd. Appoints Jo Underhill as Sales and Marketing Director, Urology/Dermatology Completing its Management Team

Donnerstag, 06.09.2012 10:05 von PR Newswire - Aufrufe: 528

PR Newswire

STAINES, England, September 6, 2012 /PRNewswire/ --

Astellas Pharma Ltd, the UK affiliate of Astellas Pharma Europe Ltd., has appointed Jo Underhill as Sales and Marketing Director, Urology/Dermatology, completing its UK management team.

     (Photo: http://photos.prnewswire.com/prnh/20120906/559442 )

Reporting directly to Mike Crooks, General Manager of Astellas Pharma Ltd, Jo's priorities will include the maintenance of Astellas' leadership position in urology including the imminent launch of several new brands.   In her new role, Jo will also be responsible for maintaining and developing Astellas' portfolio of novel and established treatments in the area of Dermatology.

Jo Underhill has been Divisional Sales Manager at Astellas Pharma Ltd. since November 2010, having joined Astellas in 2008 as National Sales Manager for Urology/Dermatology. A qualified nurse, she previously held sales and marketing roles at Roche and Schering Plough.

"In her four years at Astellas, Jo has proven herself and has played an important role in supporting our urology portfolio," said Mike Crooks, General Manager, Astellas Pharma Ltd. "APL achieved £100 million in sales by March 2010, and £300 million in cumulative sales in 2012.  Her arrival into this new role completes our UK Management Team and - with a series of product launches in planning - we now look forward to maintaining and growing our position across all of our therapy areas."

Commenting on her appointment, Jo Underhill said: "This a very exciting time for the company as we focus on both maintaining leadership and bringing novel therapies to market that have the potential to transform patients' lives. As we all know, the NHS is undergoing considerable changes and is under significant financial constraints, so - more than ever - Astellas' focus remains on satisfying the needs of our stakeholders through carefully conceived strategies with a firm basis on evidence."

Astellas Pharma Europe Ltd., the European headquarters of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, operates 21 affiliate offices located across Europe, the Middle East and Africa.  The UK business is responsible for managing and expanding the company's portfolio in six therapeutic areas: Transplantation, Urology, Dermatology, Anti-Infectives, Pain management and more recently Oncology, reinforcing Astellas' commitment to bring new and effective therapies to market in areas where unmet needs still exist.

Notes to Editors

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is the European headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 4,300 staff across these regions. For more information about Astellas Pharma Europe, please visit http://www.astellas.eu.

Mehr Nachrichten kostenlos abonnieren
E-Mail-Adresse
Ich möchte Benachrichtigungen von ARIVA.DE erhalten.
Ja, ich habe die Datenschutzhinweise gelesen und akzeptiert (Pflichtfeld).

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Kurse

  
14,545
+0,83%
Astellas Pharma Realtime-Chart